These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 30717814

  • 1. Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease.
    Hanseeuw BJ, Lopera F, Sperling RA, Norton DJ, Guzman-Velez E, Baena A, Pardilla-Delgado E, Schultz AP, Gatchel J, Jin D, Chen K, Reiman EM, Johnson KA, Quiroz YT.
    Alzheimers Res Ther; 2019 Feb 04; 11(1):17. PubMed ID: 30717814
    [Abstract] [Full Text] [Related]

  • 2. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease.
    Quiroz YT, Sperling RA, Norton DJ, Baena A, Arboleda-Velasquez JF, Cosio D, Schultz A, Lapoint M, Guzman-Velez E, Miller JB, Kim LA, Chen K, Tariot PN, Lopera F, Reiman EM, Johnson KA.
    JAMA Neurol; 2018 May 01; 75(5):548-556. PubMed ID: 29435558
    [Abstract] [Full Text] [Related]

  • 3. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
    Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST.
    J Neurosci; 2007 Jun 06; 27(23):6174-84. PubMed ID: 17553989
    [Abstract] [Full Text] [Related]

  • 4. PET evidence of preclinical cerebellar amyloid plaque deposition in autosomal dominant Alzheimer's disease-causing Presenilin-1 E280A mutation carriers.
    Ghisays V, Lopera F, Goradia DD, Protas HD, Malek-Ahmadi MH, Chen Y, Devadas V, Luo J, Lee W, Baena A, Bocanegra Y, Guzmán-Vélez E, Pardilla-Delgado E, Vila-Castelar C, Fox-Fuller JT, Hu N, Clayton D, Thomas RG, Alvarez S, Espinosa A, Acosta-Baena N, Giraldo MM, Rios-Romenets S, Langbaum JB, Chen K, Su Y, Tariot PN, Quiroz YT, Reiman EM, API ADAD Colombia Trial Group.
    Neuroimage Clin; 2021 Jun 06; 31():102749. PubMed ID: 34252876
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study.
    Sanchez JS, Hanseeuw BJ, Lopera F, Sperling RA, Baena A, Bocanegra Y, Aguillon D, Guzmán-Vélez E, Pardilla-Delgado E, Ramirez-Gomez L, Vila-Castelar C, Martinez JE, Fox-Fuller JT, Ramos C, Ochoa-Escudero M, Alvarez S, Jacobs HIL, Schultz AP, Gatchel JR, Becker JA, Katz SR, Mayblyum DV, Price JC, Reiman EM, Johnson KA, Quiroz YT.
    Alzheimers Res Ther; 2021 Jan 15; 13(1):27. PubMed ID: 33451357
    [Abstract] [Full Text] [Related]

  • 6. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types.
    Villemagne VL, Ataka S, Mizuno T, Brooks WS, Wada Y, Kondo M, Jones G, Watanabe Y, Mulligan R, Nakagawa M, Miki T, Shimada H, O'Keefe GJ, Masters CL, Mori H, Rowe CC.
    Arch Neurol; 2009 Dec 15; 66(12):1537-44. PubMed ID: 20008660
    [Abstract] [Full Text] [Related]

  • 7. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden.
    Buckley RF, Hanseeuw B, Schultz AP, Vannini P, Aghjayan SL, Properzi MJ, Jackson JD, Mormino EC, Rentz DM, Sperling RA, Johnson KA, Amariglio RE.
    JAMA Neurol; 2017 Dec 01; 74(12):1455-1463. PubMed ID: 28973551
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Entorhinal cortex tau, amyloid-β, cortical thickness and memory performance in non-demented subjects.
    Knopman DS, Lundt ES, Therneau TM, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Machulda MM, Boeve BF, Jones DT, Graff-Radford J, Albertson SM, Schwarz CG, Petersen RC, Jack CR.
    Brain; 2019 Apr 01; 142(4):1148-1160. PubMed ID: 30759182
    [Abstract] [Full Text] [Related]

  • 10. The correlation between striatal and cortical binding ratio of 11C-PiB-PET in amyloid-uptake-positive patients.
    Sauerbeck J, Ishii K, Hosokawa C, Kaida H, Scheiwein FT, Hanaoka K, Rominger A, Brendel M, Bartenstein P, Murakami T.
    Ann Nucl Med; 2018 Jul 01; 32(6):398-403. PubMed ID: 29730823
    [Abstract] [Full Text] [Related]

  • 11. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
    Rodriguez-Vieitez E, Saint-Aubert L, Carter SF, Almkvist O, Farid K, Schöll M, Chiotis K, Thordardottir S, Graff C, Wall A, Långström B, Nordberg A.
    Brain; 2016 Mar 01; 139(Pt 3):922-36. PubMed ID: 26813969
    [Abstract] [Full Text] [Related]

  • 12. Comparing amyloid-β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease.
    Chen CD, Joseph-Mathurin N, Sinha N, Zhou A, Li Y, Friedrichsen K, McCullough A, Franklin EE, Hornbeck R, Gordon B, Sharma V, Cruchaga C, Goate A, Karch C, McDade E, Xiong C, Bateman RJ, Ghetti B, Ringman JM, Chhatwal J, Masters CL, McLean C, Lashley T, Su Y, Koeppe R, Jack C, Klunk WE, Morris JC, Perrin RJ, Cairns NJ, Benzinger TLS.
    Acta Neuropathol; 2021 Oct 01; 142(4):689-706. PubMed ID: 34319442
    [Abstract] [Full Text] [Related]

  • 13. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study.
    Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, Langbaum JB, Ayutyanont N, Roontiva A, Thiyyagura P, Lee W, Mo H, Lopez L, Moreno S, Acosta-Baena N, Giraldo M, Garcia G, Reiman RA, Huentelman MJ, Kosik KS, Tariot PN, Lopera F, Reiman EM.
    Lancet Neurol; 2012 Dec 01; 11(12):1057-65. PubMed ID: 23137949
    [Abstract] [Full Text] [Related]

  • 14. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study.
    Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ, Joseph-Mathurin N, Feldman R, Fitzpatrick CD, Sparks KP, Levin J, Berman SB, Renton AE, Esposito BT, Fernandez MV, Sung YJ, Lee JH, Klunk WE, Hofmann A, Noble JM, Graff-Radford N, Mori H, Salloway SM, Masters CL, Martins R, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Gordon BA, Benzinger TLS, Fox NC, Schofield PR, Fagan AM, Goate AM, Morris JC, Bateman RJ, Johnson KA, Sperling RA, Dominantly Inherited Alzheimer's Network Investigators.
    Lancet Neurol; 2022 Feb 01; 21(2):140-152. PubMed ID: 35065037
    [Abstract] [Full Text] [Related]

  • 15. BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease.
    Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, Maruff P, Snyder PJ, Masters CL, Allegri R, Chhatwal J, Farlow MR, Graff-Radford NR, Laske C, Levin J, McDade E, Ringman JM, Rossor M, Salloway S, Schofield PR, Holtzman DM, Morris JC, Bateman RJ, Dominantly Inherited Alzheimer Network.
    Brain; 2016 Oct 01; 139(Pt 10):2766-2777. PubMed ID: 27521573
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease.
    Vila-Castelar C, Muñoz N, Papp KV, Amariglio RE, Baena A, Guzmán-Vélez E, Bocanegra Y, Sanchez JS, Reiman EM, Johnson KA, Sperling RA, Lopera F, Rentz DM, Quiroz YT.
    Alzheimers Res Ther; 2020 Sep 10; 12(1):104. PubMed ID: 32912283
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.